Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations (Q37857257)

24 August 2017

1 reference

title

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations (English)

1 reference

24 August 2017

1 reference

David Burt

1

1 reference

24 August 2017

Corey Mallett

2

1 reference

24 August 2017

Martin Plante

3

1 reference

24 August 2017

Joseph Zimmermann

4

1 reference

24 August 2017

Krikor Torossian

5

1 reference

24 August 2017

Louis Fries

6

1 reference

24 August 2017

1 March 2011

1 reference

Expert Review of Vaccines

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

3

1 reference

24 August 2017

365-375

1 reference

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

24 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Facial expression of children receiving immunizations: a principal components analysis of the child facial coding system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Studies on the usefulness of intranasal inactivated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Sublingual vaccination with influenza virus protects mice against lethal viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Immunostimulating complexes (ISCOMs) for nasal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

NALT- versus Peyer's-patch-mediated mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Protollin: a novel adjuvant for intranasal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Studies of Porins: Spontaneously Transferred from Whole Cells and Reconstituted from Purified Proteins of Neisseria gonorrhoeae and Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Assessment of signs of influenza illness in the ferret model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

A nasal proteosome adjuvant activates microglia and prevents amyloid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

21 January 2018

Nasal vaccine innovation

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Prevention and control of influenza. Role of vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Intranasal Influenza Vaccine in a Working Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.172

21 January 2018

Identifiers

DOI

10.1586/ERV.10.172

1 reference

release_xw53ylkdcrgcbgfbha7khb2tkm

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xw53ylkdcrgcbgfbha7khb2tkm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference